Serica

Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D., as Chief Technology Officer and Jayne M. Gansler as Chief People Officer

Retrieved on: 
Thursday, October 22, 2020
Biotechnology, Pharmaceutical, Health, Seres, Chief technology officer, Serica

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the expansion of its leadership team with the appointments of David S. Ege, Ph.D., as Executive Vice President, Chief Technology Officer (CTO) and Jayne M. Gansler as Executive Vice President, Chief People Officer (CPO).

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the expansion of its leadership team with the appointments of David S. Ege, Ph.D., as Executive Vice President, Chief Technology Officer (CTO) and Jayne M. Gansler as Executive Vice President, Chief People Officer (CPO).
  • Earlier this year, we appointed Lisa von Moltke, M.D., FCP, as Seres Chief Medical Officer and Terri Young, Ph.D., R.Ph., as Chief Commercial and Strategy Officer, and we are pleased to now add two additional highly accomplished professionals to Seres executive team.
  • Jayne has held critical roles building global biopharmaceutical companies and this experience will be central to attracting top talent to Seres, an effort which is well underway.
  • I am honored to work with such a talented and diverse team, said Eric D. Shaff, President and Chief Executive Officer of Seres.

Seres Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Monday, September 14, 2020
Infectious diseases, Biotechnology, Pharmaceutical, Health, Serica, Tocharians, NASDAQ, Microbiome, Finance

(Nasdaq:MCRB) today announced that management will present at two upcoming investor conferences:

Key Points: 
  • (Nasdaq:MCRB) today announced that management will present at two upcoming investor conferences:
    H.C. Wainwright 22nd Annual Global Investment Conference: Seres will present a corporate overview on Wednesday, September 16 at 11:00 a.m.
  • Oppenheimer Fall Healthcare Summit: Seres will present a corporate overview on Wednesday, September 23 at 11:40 a.m.
  • A live audio webcast of each presentation will be available under the Investors and Media section of Seres website.
  • Seres Therapeutics, Inc., (Nasdaq:MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease.

Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, August 11, 2020
Biotechnology, Pharmaceutical, Health, Financial economics, Finance, Stock market, Initial public offering, Corporate finance, Financial markets, Prospectus, Shelf registration, U.S. Securities and Exchange Commission, Serica, Stock, Option

As part of this offering, Seres intends to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common stock on the same terms and conditions.

Key Points: 
  • As part of this offering, Seres intends to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common stock on the same terms and conditions.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the proposed offering.
  • All of the shares in the proposed offering are to be sold by Seres.
  • The common stock described are being offered by Seres pursuant to a shelf registration statement on Form S-3, including a prospectus, which was automatically effective upon filing on August 11, 2020.

Seres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, July 28, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Serica, Tocharians

Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported financial results from the second quarter ended June 30, 2020, and provided an operational update.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported financial results from the second quarter ended June 30, 2020, and provided an operational update.
  • In addition, we expect that positive ECOSPOR III results would also be a validating milestone for Seres pipeline of microbiome therapeutics.
  • ECOSPOR III study results remain blinded to the Company and topline study results are anticipated in August 2020.
  • Seres ended the second quarter with approximately $63.9 million in cash, cash equivalents and investments compared with $75.1 million at the end of the first quarter 2020.

Seres Therapeutics Appoints Lisa von Moltke, M.D., as Chief Medical Officer

Retrieved on: 
Monday, April 6, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Companies, Moltke, Genzyme, Serica, Sanofi, Biotechnology companies, Life sciences

Seres Therapeutics, Inc. , (Nasdaq: MCRB) today announced the appointment of Lisa von Moltke, M.D., FCP, as Executive Vice President and Chief Medical Officer.

Key Points: 
  • Seres Therapeutics, Inc. , (Nasdaq: MCRB) today announced the appointment of Lisa von Moltke, M.D., FCP, as Executive Vice President and Chief Medical Officer.
  • Dr. von Moltke joins Seres with an extensive career that includes senior leadership positions at Alkermes, Sanofi Genzyme and Millennium Pharmaceuticals/Takeda Oncology.
  • View the full release here: https://www.businesswire.com/news/home/20200406005187/en/
    Lisa von Moltke, M.D., FCP, Executive Vice President and Chief Medical Officer of Seres Therapeutics (Photo: Business Wire)
    We are thrilled to welcome Dr. Lisa von Moltke as a key addition to our team.
  • Lisa is joining Seres during an especially important period ahead of our anticipated SER-109 ECOSPOR III Phase 3 clinical readout in recurrent C. difficile infection, said Eric Shaff, President and Chief Executive Officer of Seres.

Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 5, 2019
Biotechnology, Pharmaceutical, Health, Medical specialties, Medicine, Clinical medicine, Diarrhea, Autoimmune diseases, Abdominal pain, Colitis, RTT, Ulcerative colitis, Serica, David Berry

Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported financial results for the three months ended September 30, 2019 and provided a business update.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported financial results for the three months ended September 30, 2019 and provided a business update.
  • Seres continues to enroll the SER-287 Phase 2b ECO-RESET induction study in patients with active mild-to-moderate ulcerative colitis.
  • Seres expects Phase 2b ECO-RESET study top-line results in the second half of 2020.
  • As of October 31, ECOSPOR III was more than 85% enrolled, and top-line study results are expected in mid-2020.

Seres Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Friday, June 14, 2019
Health, Biotechnology, Infectious diseases, Oncology, Pharmaceutical, Finance, Money, Economy, Stock market, Corporate finance, Serica, Tocharians, Shelf registration, Stock, Option

Seres also granted the underwriters a 30-day option to purchase up to an additional 2,666,666 shares of its common stock.

Key Points: 
  • Seres also granted the underwriters a 30-day option to purchase up to an additional 2,666,666 shares of its common stock.
  • All of the shares in the offering are to be sold by Seres.
  • The common stock described are being offered by Seres pursuant to a shelf registration statement on Form S-3 (File No.
  • There can be no assurance that Seres will be able to complete the proposed offering on the anticipated terms.

Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Retrieved on: 
Wednesday, June 12, 2019
Health, Biotechnology, Infectious diseases, Oncology, Pharmaceutical, Finance, Money, Financial markets, Stock market, Corporate finance, Shelf registration, Goldman Sachs, Stock, Serica

As part of this offering, Seres intends to grant the underwriters a 30-day option to purchase up to an additional $9.0 million of shares of its common stock.

Key Points: 
  • As part of this offering, Seres intends to grant the underwriters a 30-day option to purchase up to an additional $9.0 million of shares of its common stock.
  • All of the shares in the proposed offering are to be sold by Seres.
  • Goldman Sachs & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.
  • The common stock described are being offered by Seres pursuant to a shelf registration statement on Form S-3 (No.

MindBytes BVBA Publishes First Peer-Reviewed Manuscript on Its SERES™ Methodological Framework and Demonstrates Proof-of-Concept

Retrieved on: 
Thursday, May 2, 2019
Education, Primary, Secondary, Other Education, Entertainment, Electronic Games, Surgery, Technology, Consumer electronics, Internet, Software, Practice Management, Health, Biotechnology, Clinical trials, Hospitals, Mental health, Pharmaceutical, Children, Parenting, Research, Consumer, Science, Managed care, Tocharians, Serica, SGH

In the JSG Publication, the Company describes the findings of a critical review of the serious games for health (SGH) research literature alongside the formulation of its SERES Framework.

Key Points: 
  • In the JSG Publication, the Company describes the findings of a critical review of the serious games for health (SGH) research literature alongside the formulation of its SERES Framework.
  • Therefore we developed the SERES Framework to guide SGH stakeholders.
  • Accordingly, we are pleased to formally publish on our SERES Framework, which ensures that our tools are theory-driven and evidence-based, maximizing their potential for success, says MindBytes CEO, Geert Vander Stichele.
  • MindBytes has established proof-of-concept by applying the SERES Framework in the development of an SGH, CliniPup.

Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update

Retrieved on: 
Thursday, May 2, 2019
Health, Biotechnology, Infectious diseases, Pharmaceutical, Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Colitis, Abdominal pain, Diarrhea, RTT, Ulcerative colitis, Serica, David Berry

(Nasdaq: MCRB) (Seres or the Company) today reported first quarter 2019 financial results and provided business updates.

Key Points: 
  • (Nasdaq: MCRB) (Seres or the Company) today reported first quarter 2019 financial results and provided business updates.
  • In recent months, Seres has made significant corporate and clinical progress to concentrate our resources on our highest priority therapeutic candidates with the goal of rapidly achieving key pipeline milestones.
  • Seres continues to enroll the SER-287 Phase 2b ECO-RESET induction study in patients with active mild-to-moderate ulcerative colitis.
  • The first quarter net loss was driven primarily by clinical and development expenses, personnel expenses and ongoing development of the Companys microbiome therapeutics platform.